Pharma Plants Are Rising. The Scientists Come Later.

Walk the perimeter of any of the four new Eli Lilly sites under construction in the United States and you can read the cycle on the ground: trade crews pulling conduit, project engineers in hard hats, ribbon-cuttings already on the calendar. The process engineers, the quality leads, and the regulatory writers, the people who will actually run those plants, are still a year or two from getting their offer letters. A full scientific workforce is roughly a decade from ramp.

That gap is not a sign that the onshoring push has stalled. It is the cycle.

Since 2025, pharmaceutical companies have committed more than $370 billion to U.S. manufacturing build-out, according to industry tallies cited in a recent GEN commentary. Eli Lilly alone has committed to four U.S. sites, one of them in Virginia. Merck & Co. has broken ground on a $3 billion facility in Virginia. The corridor that matters most runs through Indiana, Virginia, North Carolina, and Texas, four states where the ribbon-cuttings are landing now.

Each of those announcements reads as a hiring story. None of them is, yet.

The hiring that is happening today is construction-phase hiring: skilled trades, project engineers, and project managers. These are the crews pouring pads, running electrical, sequencing the build. They are a different population from the eventual operators of the plant, and they are on a different clock. Scientific process engineers, quality specialists, and regulatory professionals sit one to two years downstream of the ribbon-cutting. They are the people who validate a process, file the dossier, and keep the line compliant. Full workforce impact, the commentary argues, builds steadily over the next decade.

So when a regional economic developer says "we have X billion dollars of life-sciences construction under way" and a workforce lead says "we cannot find people," both can be telling the truth. They are looking at the same boom from different phases of the same boom.

The mechanism is straightforward. A new biologics plant is built before it is qualified, qualified before it is validated, validated before it runs commercial batches, and only then does the operating headcount approach steady state. Construction crews can break ground the day financing closes. Scientific hiring cannot start until a quality target product profile exists, because the people being hired are being hired to deliver that profile. The result is a multi-year phase clock that runs from capital commitment to commercial output, and a hiring curve that lags the ribbon-cutting by one to two years and the production curve by closer to ten.

CDMOs, contract development and manufacturing organizations, the firms that take a molecule from clinical through commercial production under contract, are absorbing the interim. They are not a stopgap while the new plants come online. The commentary treats them as a strategic bridge: a sponsor with a 2027 launch can run clinical and early commercial supply through a CDMO, then transition to its own facility once the line is qualified. That bridge is the part of the workforce plan that is not visible in the ribbon-cutting photos, and it is the part that determines whether a 2027 launch actually happens.

COVID exposed the dependence on overseas raw materials and capacity. The tariff threats of the last few years reinforced the supply-chain case. The capital is real and the policy logic is intact. The thing that is easy to miss, and that the source's decade-out argument spells out, is that the eventual plant workforce will not look like today's. Automation and AI are reshaping the labor mix while the steel goes up. A line that would have needed 200 operators in 2010 runs with fewer, and the operators it does need carry a different skill profile. The scientific hiring that does land in 2026 and 2027 will be hiring for a plant that does not yet exist as an operating system.

For a workforce lead or a CDMO partner, the planning question is not whether the build is real. It is which phase of the cycle you are staffing for. Construction-phase hiring is happening now in Indiana, Virginia, North Carolina, and Texas, and the trades want-ad pile-up is visible in the regional papers. CDMO capacity is the constraint for any 2026 or 2027 launch. The scientific pipeline to start building now is the one that will staff the qualified plant: process engineers, quality leads, regulatory writers. The offer letter that lands in 2027 has to come out of a relationship that started in 2025.

The next move this quarter is a phase read: which of the three are you staffing for, and does your talent plan match?